<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Clin Risk Manag</journal-id><journal-id journal-id-type="iso-abbrev">Ther Clin Risk Manag</journal-id><journal-id journal-id-type="publisher-id">Therapeutics and Clinical Risk Management</journal-id><journal-title-group><journal-title>Therapeutics and Clinical Risk Management</journal-title></journal-title-group><issn pub-type="ppub">1176-6336</issn><issn pub-type="epub">1178-203X</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26834478</article-id><article-id pub-id-type="pmc">4716756</article-id><article-id pub-id-type="doi">10.2147/TCRM.S95235</article-id><article-id pub-id-type="publisher-id">tcrm-12-059</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Video-assisted thoracic surgery reduces early postoperative stress. A single-institutional prospective randomized study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Asteriou</surname><given-names>Christos</given-names></name><xref ref-type="aff" rid="af1-tcrm-12-059">1</xref></contrib><contrib contrib-type="author"><name><surname>Lazopoulos</surname><given-names>Achilleas</given-names></name><xref ref-type="aff" rid="af1-tcrm-12-059">1</xref></contrib><contrib contrib-type="author"><name><surname>Rallis</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="af1-tcrm-12-059">1</xref></contrib><contrib contrib-type="author"><name><surname>Gogakos</surname><given-names>Apostolos S</given-names></name><xref ref-type="aff" rid="af1-tcrm-12-059">1</xref></contrib><contrib contrib-type="author"><name><surname>Paliouras</surname><given-names>Dimitrios</given-names></name><xref ref-type="aff" rid="af1-tcrm-12-059">1</xref></contrib><contrib contrib-type="author"><name><surname>Tsakiridis</surname><given-names>Kosmas</given-names></name><xref ref-type="aff" rid="af2-tcrm-12-059">2</xref></contrib><contrib contrib-type="author"><name><surname>Zissimopoulos</surname><given-names>Athanasios</given-names></name><xref ref-type="aff" rid="af3-tcrm-12-059">3</xref></contrib><contrib contrib-type="author"><name><surname>Tsavlis</surname><given-names>Drosos</given-names></name><xref ref-type="aff" rid="af4-tcrm-12-059">4</xref></contrib><contrib contrib-type="author"><name><surname>Porpodis</surname><given-names>Konstantinos</given-names></name><xref ref-type="aff" rid="af4-tcrm-12-059">4</xref></contrib><contrib contrib-type="author"><name><surname>Hohenforst-Schmidt</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="af5-tcrm-12-059">5</xref></contrib><contrib contrib-type="author"><name><surname>Kioumis</surname><given-names>Ioannis</given-names></name><xref ref-type="aff" rid="af4-tcrm-12-059">4</xref></contrib><contrib contrib-type="author"><name><surname>Organtzis</surname><given-names>John</given-names></name><xref ref-type="aff" rid="af4-tcrm-12-059">4</xref></contrib><contrib contrib-type="author"><name><surname>Zarogoulidis</surname><given-names>Konstantinos</given-names></name><xref ref-type="aff" rid="af4-tcrm-12-059">4</xref></contrib><contrib contrib-type="author"><name><surname>Zarogoulidis</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="af4-tcrm-12-059">4</xref><xref ref-type="corresp" rid="c1-tcrm-12-059"/></contrib><contrib contrib-type="author"><name><surname>Barbetakis</surname><given-names>Nikolaos</given-names></name><xref ref-type="aff" rid="af1-tcrm-12-059">1</xref></contrib></contrib-group><aff id="af1-tcrm-12-059"><label>1</label>Department of Thoracic Surgery, Theagenio Cancer Hospital, Thessaloniki, Greece</aff><aff id="af2-tcrm-12-059"><label>2</label>Cardiothoracic Surgery Department, Saint Luke Private Hospital, Panorama, Thessaloniki, Greece</aff><aff id="af3-tcrm-12-059"><label>3</label>Nuclear Medicine Department, University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece</aff><aff id="af4-tcrm-12-059"><label>4</label>Pulmonary Department-Oncology Unit, &#x0201c;G Papanikolaou&#x0201d; General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece</aff><aff id="af5-tcrm-12-059"><label>5</label>Medical Clinic I, &#x0201c;Fuerth&#x0201d; Hospital, University of Erlangen, Fuerth, Germany</aff><author-notes><corresp id="c1-tcrm-12-059">Correspondence: Paul Zarogoulidis, Pulmonary Department-Oncology Unit, &#x0201c;G Papanikolaou&#x0201d; General Hospital, Aristotle University of Thessaloniki, Exohi 1100 57010 Thessaloniki, Greece, Tel +30 697 727 1974, Fax +30 231 099 2424, Email <email>pzarog@hotmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>12</day><month>1</month><year>2016</year></pub-date><volume>12</volume><fpage>59</fpage><lpage>65</lpage><permissions><copyright-statement>&#x000a9; 2016 Asteriou et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2016</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Background</title><p>Video-assisted thoracic surgery (VATS) has been shown to effectively reduce postoperative pain, enhance mobilization of the patients, shorten in-hospital length of stay, and minimize postoperative morbidity rates. The aim of this prospective study is to evaluate neuroendocrine and respiratory parameters as stress markers in cancer patients who underwent lung wedge resections, using both mini muscle-sparing thoracotomy and VATS approach.</p></sec><sec><title>Methods</title><p>The patients were randomly allocated into two groups: Group A (n=30) involved patients who were operated on using the VATS approach, while in group B (n=30), the mini muscle-sparing thoracotomy approach was used. Neuroendocrine and biological variables assessed included blood glucose levels, C-reactive protein (CRP) levels, cortisol, epinephrine, and adrenocorticotropic hormone (ACTH) levels. Arterial oxygen (PaO<sub>2</sub>) and carbon dioxide (PaCO<sub>2</sub>) partial pressure were also evaluated. All parameters were measured at the following time points: 24 hours preoperatively (T<sub>1</sub>), 4 hours (T<sub>2</sub>), 24 hours (T<sub>3</sub>), 48 hours (T<sub>4</sub>), and 72 hours (T<sub>5</sub>), after the procedure.</p></sec><sec><title>Results</title><p>PaO<sub>2</sub> levels were significantly higher 4 and 24 hours postoperatively in group A vs group B, respectively (T<sub>2</sub>: 94.3 vs 77.9 mmHg, <italic>P</italic>=0.015, T<sub>3</sub>: 96.4 vs 88.7 mmHg, <italic>P</italic>=0.034). Blood glucose (T<sub>2</sub>: 148 vs 163 mg/dL, <italic>P</italic>=0.045, T<sub>3</sub>: 133 vs 159 mg/dL, <italic>P</italic>=0.009) and CRP values (T<sub>2</sub>: 1.6 vs 2.5 mg/dL, <italic>P</italic>=0.024, T<sub>3</sub>: 1.5 vs 2.1 mg/dL, <italic>P</italic>=0.044) were found increased in both groups 4 and 24 hours after the procedure. However, their levels were significantly lower in the VATS group of patients. ACTH and cortisol values were elevated immediately after the operation and became normal after 48 hours in both groups, without significant difference. Postoperative epinephrine levels measured in group A vs group B, respectively, (T<sub>2</sub>: 78.9 vs 115.6 ng/L, <italic>P</italic>=0.007, T<sub>3</sub>: 83.4 vs 122.5 ng/L, <italic>P</italic>=0.012, T<sub>4</sub>: 67.4 vs 102.6 ng/L, <italic>P</italic>=0.021). The levels were significantly higher in group B.</p></sec><sec><title>Conclusion</title><p>This study confirmed that minimally invasive thoracic surgery, by means of VATS, significantly reduces the acute-phase response and surgical stress, while enables better postoperative oxygenation.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>VATS</kwd><kwd>stress</kwd><kwd>markers</kwd><kwd>randomized controlled trial (RCT)</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Not many people may argue that in the last decades thoracic surgery has made a very important step toward minimally invasive techniques by utilizing video-assisted thoracic surgery (VATS), with respect to both diagnosis and treatment of early-stage lung cancer, while numerous studies support the prevalence of VATS over the classic open thoracotomy approach.<xref rid="b1-tcrm-12-059" ref-type="bibr">1</xref>&#x02013;<xref rid="b5-tcrm-12-059" ref-type="bibr">5</xref> VATS lung resections are safe and equally effective as lung resections achieved using thoracotomy.<xref rid="b6-tcrm-12-059" ref-type="bibr">6</xref>,<xref rid="b7-tcrm-12-059" ref-type="bibr">7</xref></p><p>The role of minimally invasive techniques in abdominal surgery and the impact they exert in metabolism, inflammatory, and immunological response has been well-described over the last years in the international literature.<xref rid="b8-tcrm-12-059" ref-type="bibr">8</xref> Moreover, certain studies focused on their importance in thoracic surgery.<xref rid="b9-tcrm-12-059" ref-type="bibr">9</xref> Increased surgical stress and systemic inflammatory response are associated with higher rates of morbidity and mortality. Furthermore, in cancer patients, open thoracotomy approach induces large immunologic changes, which may increase the rate of complications.<xref rid="b10-tcrm-12-059" ref-type="bibr">10</xref>,<xref rid="b11-tcrm-12-059" ref-type="bibr">11</xref></p><p>The aim of this study was to evaluate in a prospective manner certain neuroendocrine and respiratory parameters, such as postoperative oxygenation and stress markers, in cancer patients who underwent lung wedge resections, using both mini muscle-sparing thoracotomy and VATS approach.</p></sec><sec sec-type="methods|subjects"><title>Patients and methods</title><p>From September 2012 to January 2014, 60 patients undergoing elective pulmonary sublobar wedge resections were enrolled in this prospective, single-institutional, randomized study. After study approval by the Theagenio Cancer Hospital Institutional Research Ethics Committee and after written informed consent was obtained from all patients, blinded randomization, using computer-generated random allocations, was performed. The patients were randomly assigned to one of two groups: Group A (n=30) involved patients who were operated on using the VATS approach, while in group B (n=30), the mini muscle-sparing thoracotomy approach was used (<xref ref-type="fig" rid="f1-tcrm-12-059">Figure 1</xref>).</p><p>Demographic and preoperative patient data are shown in <xref ref-type="table" rid="t1-tcrm-12-059">Table 1</xref>. Age &#x0003c;75 years, forced expiratory volume in 1 second &#x02265;1 L, and American Society of Anesthesiologists Classification System &#x02264;3 were defined as the inclusion criteria. Exclusion criteria involved emergency surgery and reoperation. The study is registered at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>, number NCT01397045.</p><sec><title>Surgical strategy</title><p>In group B, access to the pleural cavity was obtained by a limited (4&#x02013;5 cm) posterolateral thoracotomy, preserving latissimus dorsi and partially dividing serratus anterior muscle. In VATS approach group, three stab incisions were made over the lateral thoracic wall (three holes technique). The lowest hole was located at the middle axillary line just above the level of the diaphragm and served as the entrance point for a 0&#x000b0; fiber-optic camera. The other two incisions were carried out at the posterolateral and the anterolateral thoracic wall, under direct thoracoscopic vision, in such a way as to facilitate the access to the pulmonary lesions. In both groups, a 60 mm endostapler was used in order to perform pulmonary wedge sublobar resection. Two 32 French chest tubes were placed upon the completion of the operation.</p></sec><sec><title>Anesthetic and postoperative management</title><p>All patients received premedication and anesthesia induction using the same method. Tracheal intubation was achieved with the use of a double-lumen tube under bronchoscopic guidance in all cases. Patients&#x02019; arterial blood pressure, electrocardiogram, central venous pressure, oxygen saturation (SpO<sub>2</sub>), end-tidal carbon dioxide (ETCO<sub>2</sub>), and blood gas values were constantly monitored. Postoperative systemic analgesia was identical for both groups. All patients were mobilized from the first postoperative day, and the thoracic tubes were removed when output was &#x0003c;200 mL in 24 hours and no air leakage was present.</p></sec><sec sec-type="methods"><title>Study endpoints</title><p>Neuroendocrine and biological variables assessed included blood glucose levels, C-reactive protein (CRP) levels, cortisol, epinephrine, and adrenocorticotropic hormone (ACTH) levels. Arterial oxygen (PaO<sub>2</sub>) and carbon dioxide (PaCO<sub>2</sub>) partial pressure were also evaluated. All parameters were measured at the following time points: 24 hours preoperatively (T<sub>1</sub>) and 4 hours (T<sub>2</sub>), 24 hours (T<sub>3</sub>), 48 hours (T<sub>4</sub>), and 72 hours (T<sub>5</sub>), after the procedure. Significant perioperative variables were also recorded and analyzed: number of the segments resected, morphology of the lesion, major cardiopulmonary complications, in-hospital length of stay, and 30-day mortality. The primary endpoint of the study was the effect of VATS on epinephrine levels. Cortisol, ACTH, blood glucose, and CRP levels served as secondary endpoints.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>Power analysis was employed to detect appropriate sample size. We have calculated that the average morbidity rate in our institution using mini muscle-sparing thoracotomy approach is about 5%. We supposed that implementation of VATS approach is expected to reduce the corresponding rates up to 30%. Setting the level of type I error (&#x003b1;) at 0.05 and the desired power of the study (1-&#x003b2;) at 80%, we calculated that each group should include at least 30 subjects (G*Power v. 3.1.2, Heinrich-Heine University, D&#x000fc;sseldorf, Germany). Statistical analysis was performed using the SPSS 17.0 software (SPSS, Chicago, IL, USA) for windows. Continuous data are presented as mean &#x000b1; standard deviation, while categorical variables are presented as absolute numbers and percentages. Normal distribution was assessed by the Kolmogorov&#x02013;Smirnov test. Univariate comparison of means was made using Student&#x02019;s <italic>t</italic>- and Mann&#x02013;Whitney <italic>U</italic>-tests when appropriate. Comparisons between percentages were assessed using the chi-square test. The level of statistical significance was set at 0.05.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Perioperative clinical data are shown in <xref ref-type="table" rid="t2-tcrm-12-059">Table 2</xref>. Duration of operation was shorter in group A; however, this did not reach statistical significance. The number of pulmonary segments resected was similar in both groups, as was as the morphology of the lesions. The pathology of each resected nodule is shown in <xref ref-type="table" rid="t3-tcrm-12-059">Table 3</xref>. Tumor nodes metastasis staging of lung cancer patients and regimen of neoadjuvant therapy used is shown in <xref ref-type="table" rid="t4-tcrm-12-059">Table 4</xref>. Furthermore, the location of resections did not significantly differ among the groups. No major cardiopulmonary complications or death were documented in the VATS group, while one patient died from pulmonary embolism on the sixth postoperative day in group B. Mean duration of hospitalization was significantly shorter in group A (5.1 vs 6.7 days, <italic>P</italic>=0.011). No conversion from VATS to open thoracotomy was necessary.</p><p>Preoperative values of neuroendocrine, biological, and respiratory variables were similar in both groups. Regarding respiratory parameters, PaO<sub>2</sub> levels were significantly higher 4 and 24 hours postoperatively in group A (T<sub>2</sub>: 94.3 vs 77.9 mmHg, <italic>P</italic>=0.015, T<sub>3</sub>: 96.4 vs 88.7 mmHg, <italic>P</italic>=0.034), while Paco<sub>2</sub> levels did not differ between the groups (<xref ref-type="fig" rid="f2-tcrm-12-059">Figure 2</xref>). Blood glucose (T<sub>2</sub>: 148 vs 163 mg/dL, <italic>P</italic>=0.045, T<sub>3</sub>: 133 vs 159 mg/dL, <italic>P</italic>=0.009) and CRP values (T<sub>2</sub>: 1.6 vs 2.5 mg/dL, <italic>P</italic>=0.024, T<sub>3</sub>: 1.5 vs 2.1 mg/dL, <italic>P</italic>=0.044) were found to be increased in both groups 4 and 24 hours after the procedure. However, their levels were significantly lower in the VATS group of patients (<xref ref-type="fig" rid="f3-tcrm-12-059">Figure 3</xref>). ACTH and cortisol values were elevated immediately after the operation and became normal after 48 hours in both groups, without significant difference (<xref ref-type="fig" rid="f4-tcrm-12-059">Figure 4</xref>). Postoperative epinephrine levels measured (T<sub>2</sub>: 78.9 vs 115.6 ng/L, <italic>P</italic>=0.007, T<sub>3</sub>: 83.4 vs 122.5 ng/L, <italic>P</italic>=0.012, T<sub>4</sub>: 67.4 vs 102.6 ng/L, <italic>P</italic>=0.021) were significantly higher in group B (<xref ref-type="fig" rid="f4-tcrm-12-059">Figure 4</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The role of VATS in the treatment of patients with pulmonary nodules has been upgraded during the last years, and the majority of thoracic surgeons consider it as the most suitable approach. The advantages of VATS over thoracotomy have been well-established by numerous studies. Less postoperative pain, better mobilization of the arm and shoulder, shorter duration of hospitalization, and less morbidity in contrast to thoracotomy characterize VATS procedures.<xref rid="b12-tcrm-12-059" ref-type="bibr">12</xref>&#x02013;<xref rid="b14-tcrm-12-059" ref-type="bibr">14</xref></p><p>All patients who received neoadjuvant therapy, as shown in <xref ref-type="table" rid="t1-tcrm-12-059">Table 1</xref>, were initially operated on for malignancy located in organs other than the lungs (eg, breast, colon, etc). Therefore, these first operations were followed by neoadjuvant therapy when appropriate. Neoadjuvant therapy was performed before the pulmonary resection. The minimum time interval between the last therapy and the pulmonary resection was at least 1 month. It is unlikely that stress variables&#x02019; levels could be affected after this time interval. Moreover, baseline measurements were not statistically significant, and both groups included similar proportion of patients who had received neoadjuvant therapy.</p><p>This study confirmed that VATS is associated with significantly higher postoperative PaO<sub>2</sub> values. Elevated PaO<sub>2</sub> levels imply optimum oxygenation, possibly attributed to the reduced postoperative pain experienced in patients operated using the thoracoscopic approach. Lower PaO<sub>2</sub> levels in the open-approach group correlate with ineffective postoperative respiratory function due to increased thoracotomy related pain.<xref rid="b15-tcrm-12-059" ref-type="bibr">15</xref> PaCO<sub>2</sub> levels recorded were similar in both groups. CO<sub>2</sub> exchange in alveoli is independent from the approach used and does not relate to postoperative thoracotomy pain.<xref rid="b16-tcrm-12-059" ref-type="bibr">16</xref></p><p>The stress response to surgery, with the production of mediators, cytokines, acute-phase proteins, adrenocorticoids, and catecholamines is influenced by the degree of surgical trauma, general anesthesia, and analgesics. Both general anesthesia and postoperative analgesic treatment were identical for all patients included in this study.</p><p>Lower insulin levels after induction of anesthesia and during surgery, along with decreased peripheral use of insulin due to perioperative increased &#x0201c;insulin resistance&#x0201d; effect, resulted in elevated concentration of blood glucose in surgical patients. Connection between elevated glucose levels after surgery and intensity of surgical injury has already been described.<xref rid="b17-tcrm-12-059" ref-type="bibr">17</xref> In correlation with these findings, patients allocated to group B were characterized by significantly elevated blood glucose levels, which returned to normal on the third postoperative day. On the contrary, VATS group of patients experienced a milder postoperative hyperglycemia.</p><p>CRP is an acute-phase response marker produced in the liver. Along with interleukin-6, fibrinogen, and other proteins, CRP acts as an inflammatory mediator. Minimally invasive thoracic surgery, utilizing VATS, is associated with minor increase in serum levels of these mediators,<xref rid="b18-tcrm-12-059" ref-type="bibr">18</xref> due to limited trauma. Reduced inflammatory response in group A was confirmed in this study.</p><p>Increase of ACTH during the operation results from stimulation of the anterior pituitary by hypothalamic releasing factors.<xref rid="b19-tcrm-12-059" ref-type="bibr">19</xref> Surgery has been recognized as one of the most potent activators of ACTH secretion.<xref rid="b17-tcrm-12-059" ref-type="bibr">17</xref> ACTH in turn stimulates the adrenal cortical secretion of glucocorticoids, thus contributing to elevated serum levels of cortisol. ACTH and cortisol levels are strongly related. No significant difference between two groups of this trial was recorded regarding postoperative measurements of these stress markers. As a result, the degree of surgical trauma itself does not significantly influence the stress response as far as ACTH and cortisol values are concerned. Identical changes in postoperative levels of these hormones in both groups are probably attributed to general anesthesia in combination with the extent of pulmonary resection.</p><p>Catecholamine levels increase as a result of the hypothalamic activation of the sympathetic autonomous nervous system and the stimulation of the adrenal medulla. Epinephrine is a strong stress indicator.<xref rid="b17-tcrm-12-059" ref-type="bibr">17</xref> Postoperative epinephrine levels recorded in this study were significantly higher in group B in comparison with group A. In addition, even 72 hours after the procedure, these levels remained elevated. This finding is consistent with a strong correlation between the epinephrine concentration increase and the extent of the surgical trauma, which is also verified by several studies.<xref rid="b18-tcrm-12-059" ref-type="bibr">18</xref></p><p>In conclusion, this study confirmed that minimally invasive thoracic surgery, by means of VATS, significantly reduces the acute-phase response and surgical stress, while enabling better postoperative oxygenation. Larger randomized trials are expected to illuminate the impact of these important findings on the treatment of cancer patients and establish VATS as the approach of choice.</p></sec></body><back><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-tcrm-12-059"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>SR</given-names></name><name><surname>Leaver</surname><given-names>HA</given-names></name><name><surname>Yap</surname><given-names>PL</given-names></name><etal/></person-group><article-title>Acute phase responses following minimal access and conventional thoracic surgery</article-title><source>Eur J Cardiothorac Surg</source><year>2001</year><volume>20</volume><fpage>455</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">11509263</pub-id></element-citation></ref><ref id="b2-tcrm-12-059"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitson</surname><given-names>BA</given-names></name><name><surname>D&#x02019;Cunha</surname><given-names>J</given-names></name><name><surname>Andrade</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity</article-title><source>Ann Thorac Surg</source><year>2008</year><volume>86</volume><fpage>1735</fpage><lpage>1744</lpage><pub-id pub-id-type="pmid">19021967</pub-id></element-citation></ref><ref id="b3-tcrm-12-059"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koizumi</surname><given-names>K</given-names></name><name><surname>Haraguchi</surname><given-names>S</given-names></name><name><surname>Hirata</surname><given-names>T</given-names></name><etal/></person-group><article-title>Video-assisted lobectomy in elderly lung cancer patients</article-title><source>Jpn J Thorac Cardiovasc Surg</source><year>2002</year><volume>50</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">11855094</pub-id></element-citation></ref><ref id="b4-tcrm-12-059"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muraoka</surname><given-names>M</given-names></name><name><surname>Oka</surname><given-names>T</given-names></name><name><surname>Akamine</surname><given-names>S</given-names></name><etal/></person-group><article-title>Video-assisted thoracic surgery lobectomy reduces the morbidity after surgery for stage I non-small cell lung cancer</article-title><source>Jpn J Thorac Cardiovasc Surg</source><year>2006</year><volume>54</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">16519128</pub-id></element-citation></ref><ref id="b5-tcrm-12-059"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitson</surname><given-names>BA</given-names></name><name><surname>Andrade</surname><given-names>RS</given-names></name><name><surname>Boettcher</surname><given-names>A</given-names></name><etal/></person-group><article-title>Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer</article-title><source>Ann Thorac Surg</source><year>2007</year><volume>83</volume><fpage>1965</fpage><lpage>1970</lpage><pub-id pub-id-type="pmid">17532379</pub-id></element-citation></ref><ref id="b6-tcrm-12-059"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirby</surname><given-names>TJ</given-names></name><name><surname>Rice</surname><given-names>TW</given-names></name></person-group><article-title>Thoracoscopic lobectomy</article-title><source>Ann Thorac Surg</source><year>1993</year><volume>56</volume><fpage>784</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">8397498</pub-id></element-citation></ref><ref id="b7-tcrm-12-059"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugi</surname><given-names>K</given-names></name><name><surname>Kaneda</surname><given-names>Y</given-names></name><name><surname>Esato</surname><given-names>K</given-names></name></person-group><article-title>Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage IA lung cancer</article-title><source>World J Surg</source><year>2000</year><volume>24</volume><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10594199</pub-id></element-citation></ref><ref id="b8-tcrm-12-059"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puggioni</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>LL</given-names></name></person-group><article-title>A metaanalysis of laparoscopic cholecystectomy in patients with cirrhosis</article-title><source>J Am Coll Surg</source><year>2003</year><volume>197</volume><fpage>921</fpage><lpage>926</lpage><pub-id pub-id-type="pmid">14644279</pub-id></element-citation></ref><ref id="b9-tcrm-12-059"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>WS</given-names></name><name><surname>Leaver</surname><given-names>HA</given-names></name><name><surname>Yap</surname><given-names>PL</given-names></name></person-group><article-title>The immune response to surgery: conventional and video assisted thorascopic pulmonary lobectomy</article-title><person-group person-group-type="editor"><name><surname>Yim</surname><given-names>APC</given-names></name></person-group><source>Minimal Access Cardiothoracic Surgery</source><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Saunders</publisher-name><year>1999</year><fpage>127</fpage><lpage>134</lpage></element-citation></ref><ref id="b10-tcrm-12-059"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sietses</surname><given-names>C</given-names></name><name><surname>Havenith</surname><given-names>CE</given-names></name><name><surname>Eijsbouts</surname><given-names>QA</given-names></name><etal/></person-group><article-title>Laparoscopic surgery preserves monocyte-mediated tumor cell killing in contrast to the conventional approach</article-title><source>Surg Endosc</source><year>2000</year><volume>14</volume><fpage>456</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">10858471</pub-id></element-citation></ref><ref id="b11-tcrm-12-059"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sietses</surname><given-names>C</given-names></name><name><surname>Beelen</surname><given-names>RH</given-names></name><name><surname>Meijer</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immunological consequences of laparoscopic surgery, speculations on the cause and clinical implications</article-title><source>Langenbecks Arch Surg</source><year>1999</year><volume>384</volume><fpage>250</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">10437613</pub-id></element-citation></ref><ref id="b12-tcrm-12-059"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>WS</given-names></name></person-group><article-title>Major pulmonary resection</article-title><person-group person-group-type="editor"><name><surname>Walker</surname><given-names>WS</given-names></name></person-group><source>Video-assisted Thoracic Surgery</source><publisher-loc>Oxford, UK</publisher-loc><publisher-name>Isis Medical Media</publisher-name><year>1999</year><fpage>135</fpage><lpage>159</lpage></element-citation></ref><ref id="b13-tcrm-12-059"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>TD</given-names></name><name><surname>Black</surname><given-names>D</given-names></name><name><surname>Bannon</surname><given-names>PG</given-names></name><etal/></person-group><article-title>Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>2553</fpage><lpage>2562</lpage><pub-id pub-id-type="pmid">19289625</pub-id></element-citation></ref><ref id="b14-tcrm-12-059"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yim</surname><given-names>AP</given-names></name><name><surname>Wan</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>TW</given-names></name><etal/></person-group><article-title>VATS lobectomy reduces cytokine responses compared with conventional surgery</article-title><source>Ann Thorac Surg</source><year>2000</year><volume>70</volume><fpage>243</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">10921716</pub-id></element-citation></ref><ref id="b15-tcrm-12-059"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catley</surname><given-names>DM</given-names></name><name><surname>Thornton</surname><given-names>C</given-names></name><name><surname>Jordan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pronounced, episodic oxygen desaturation in the postoperative period: its association with ventilatory pattern and analgesic regimen</article-title><source>Anesthesiology</source><year>1985</year><volume>63</volume><fpage>20</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">4014768</pub-id></element-citation></ref><ref id="b16-tcrm-12-059"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tschernko</surname><given-names>EM</given-names></name><name><surname>Hofer</surname><given-names>S</given-names></name><name><surname>Bieglmayer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Early postoperative stress: video-assisted resection/lobectomy vs conventional axillary thoracotomy</article-title><source>Chest</source><year>1996</year><volume>109</volume><fpage>1636</fpage><lpage>1642</lpage><pub-id pub-id-type="pmid">8769523</pub-id></element-citation></ref><ref id="b17-tcrm-12-059"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desborough</surname><given-names>JP</given-names></name></person-group><article-title>The stress response to trauma and surgery</article-title><source>Br J Anaesth</source><year>2000</year><volume>85</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">10927999</pub-id></element-citation></ref><ref id="b18-tcrm-12-059"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>WS</given-names></name><name><surname>Leaver</surname><given-names>HA</given-names></name></person-group><article-title>Immunologic and stress responses following video-assisted thoracic surgery and open pulmonary lobectomy in early stage lung cancer</article-title><source>Thorac Surg Clin</source><year>2007</year><volume>17</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">17626402</pub-id></element-citation></ref><ref id="b19-tcrm-12-059"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyons</surname><given-names>FM</given-names></name><name><surname>Meeran</surname><given-names>K</given-names></name></person-group><article-title>The physiology of the endocrine system</article-title><source>Int Anesthesiol Clin</source><year>1997</year><volume>35</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">9444528</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-tcrm-12-059" position="float"><label>Figure 1</label><caption><p>Flow chart depicting trial phases.</p><p><bold>Abbreviation:</bold> VATS, video-assisted thoracic surgery.</p></caption><graphic xlink:href="tcrm-12-059Fig1"/></fig><fig id="f2-tcrm-12-059" position="float"><label>Figure 2</label><caption><p>Blood gas levels.</p><p><bold>Notes:</bold> (<bold>A</bold>) Arterial oxygen (PaO<sub>2</sub>) (*<italic>P</italic>=0.015, **<italic>P</italic>=0.034) and (<bold>B</bold>) carbon dioxide (PaCO<sub>2</sub>) partial pressure data between groups at the measured time points: 24 hours preoperatively (T<sub>1</sub>) and 4 hours (T<sub>2</sub>), 24 hours (T<sub>3</sub>), 48 hours (T<sub>4</sub>), and 72 hours (T<sub>5</sub>), after the procedure.</p><p><bold>Abbreviation:</bold> VATS, video-assisted thoracic surgery.</p></caption><graphic xlink:href="tcrm-12-059Fig2"/></fig><fig id="f3-tcrm-12-059" position="float"><label>Figure 3</label><caption><p>Glucose and c-reactive protein levels.</p><p><bold>Notes:</bold> (<bold>A</bold>) Levels of blood glucose (*<italic>P</italic>=0.045, **<italic>P</italic>=0.009) and (<bold>B</bold>) CRP (*<italic>P</italic>=0.024, **<italic>P</italic>=0.044) between groups at the measured time-points: 24 hours preoperatively (T<sub>1</sub>), 4 hours (T<sub>2</sub>), 24 hours (T<sub>3</sub>), 48 hours (T<sub>4</sub>), and 72 hours (T<sub>5</sub>), after the procedure.</p><p><bold>Abbreviations:</bold> VATS, video-assisted thoracic surgery; CRP, C-reactive protein.</p></caption><graphic xlink:href="tcrm-12-059Fig3"/></fig><fig id="f4-tcrm-12-059" position="float"><label>Figure 4</label><caption><p>Hormone levels.</p><p><bold>Notes:</bold> (<bold>A</bold>) Levels of ACTH, (<bold>B</bold>) cortisol, and (<bold>C</bold>) epinephrine (*<italic>P</italic>=0.007, **<italic>P</italic>=0.012, ***<italic>P</italic>=0.021) between groups at the measured time-points: 24 hours preoperatively (T<sub>1</sub>), 4 hours (T<sub>2</sub>), 24 hours (T<sub>3</sub>), 48 hours (T<sub>4</sub>), and 72 hours (T<sub>5</sub>), after the procedure.</p><p><bold>Abbreviations:</bold> VATS, video-assisted thoracic surgery; ACTH, adrenocorticotropic hormone.</p></caption><graphic xlink:href="tcrm-12-059Fig4"/></fig><table-wrap id="t1-tcrm-12-059" position="float"><label>Table 1</label><caption><p>Preoperative patients&#x02019; characteristics per treatment group assigned</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">VATS (n=30)</th><th valign="top" align="left" rowspan="1" colspan="1">Thoracotomy (n=30)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">57.7&#x000b1;18.7</td><td valign="top" align="left" rowspan="1" colspan="1">60.8&#x000b1;14.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.132</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex (male)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (56.7)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (60)</td><td valign="top" align="left" rowspan="1" colspan="1">0.463</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Height (m)</td><td valign="top" align="left" rowspan="1" colspan="1">1.7&#x000b1;0.1</td><td valign="top" align="left" rowspan="1" colspan="1">1.7&#x000b1;0.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.678</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Weight (kg)</td><td valign="top" align="left" rowspan="1" colspan="1">79.6&#x000b1;14.7</td><td valign="top" align="left" rowspan="1" colspan="1">80.2&#x000b1;16.5</td><td valign="top" align="left" rowspan="1" colspan="1">0.583</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">27.3&#x000b1;4.1</td><td valign="top" align="left" rowspan="1" colspan="1">27.4&#x000b1;5.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.734</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (L)</td><td valign="top" align="left" rowspan="1" colspan="1">2.3&#x000b1;0.7</td><td valign="top" align="left" rowspan="1" colspan="1">2.4&#x000b1;0.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.415</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FVC (L)</td><td valign="top" align="left" rowspan="1" colspan="1">3.1&#x000b1;0.9</td><td valign="top" align="left" rowspan="1" colspan="1">3.2&#x000b1;0.8</td><td valign="top" align="left" rowspan="1" colspan="1">0.372</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub>/FVC</td><td valign="top" align="left" rowspan="1" colspan="1">0.7&#x000b1;0.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.7&#x000b1;0.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.653</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">ASA classification</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Class 1</td><td valign="top" align="left" rowspan="1" colspan="1">7 (23.3)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">0.732</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Class 2</td><td valign="top" align="left" rowspan="1" colspan="1">17 (56.7)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (46.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Class 3</td><td valign="top" align="left" rowspan="1" colspan="1">6 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (23.3)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">Neoadjuvant therapy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;None</td><td valign="top" align="left" rowspan="1" colspan="1">19 (63.3)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (56.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.379</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Chemotherapy</td><td valign="top" align="left" rowspan="1" colspan="1">7 (23.3)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (26.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Chemotherapy and Radiotherapy</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.4)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (16.6)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Coronary artery disease</td><td valign="top" align="left" rowspan="1" colspan="1">5 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.208</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.765</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension</td><td valign="top" align="left" rowspan="1" colspan="1">16 (53.3)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (60)</td><td valign="top" align="left" rowspan="1" colspan="1">0.456</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td valign="top" align="left" rowspan="1" colspan="1">14 (46.7)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (40)</td><td valign="top" align="left" rowspan="1" colspan="1">0.319</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-tcrm-12-059"><p><bold>Note:</bold> Data are mean &#x000b1; standard deviation or absolute numbers (percentages).</p></fn><fn id="tfn2-tcrm-12-059"><p><bold>Abbreviations:</bold> VATS, video-assisted thoracic surgery; FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity; ASA, American Society of Anesthesiologists.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-tcrm-12-059" position="float"><label>Table 2</label><caption><p>Perioperative clinical parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">VATS (n=30)</th><th valign="top" align="left" rowspan="1" colspan="1">Thoracotomy (n=30)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of operation (minutes)</td><td valign="top" align="left" rowspan="1" colspan="1">63.5&#x000b1;3.1</td><td valign="top" align="left" rowspan="1" colspan="1">65.1&#x000b1;3.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.057</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Segments resected</td><td valign="top" align="left" rowspan="1" colspan="1">2.3&#x000b1;1.5</td><td valign="top" align="left" rowspan="1" colspan="1">2.4&#x000b1;1.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.534</td></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">Location of segments resected</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Right upper lobe</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.695</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Right middle lobe</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (20)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Right lower lobe</td><td valign="top" align="left" rowspan="1" colspan="1">9 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Left upper lobe</td><td valign="top" align="left" rowspan="1" colspan="1">6 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (23.3)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Left lower lobe</td><td valign="top" align="left" rowspan="1" colspan="1">8 (26.7)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (26.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="4" valign="top" align="left" rowspan="1">Morphology of the nodule</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Non-neoplastic</td><td valign="top" align="left" rowspan="1" colspan="1">11 (36.7)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (46.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.876</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Neoplastic primary malignant</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Neoplastic secondary malignant</td><td valign="top" align="left" rowspan="1" colspan="1">15 (50)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (43.3)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Major cardiopulmonary complications</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.986</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">In-hospital stay (days)</td><td valign="top" align="left" rowspan="1" colspan="1">5.1&#x000b1;1.4</td><td valign="top" align="left" rowspan="1" colspan="1">6.7&#x000b1;1.3</td><td valign="top" align="left" rowspan="1" colspan="1"><bold>0.011</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">30-day mortality</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.986</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-tcrm-12-059"><p><bold>Notes:</bold> Data are mean &#x000b1; standard deviation or absolute numbers (percentages). Bold indicates a statistically significant value.</p></fn><fn id="tfn4-tcrm-12-059"><p><bold>Abbreviation:</bold> VATS, video assisted thoracic surgery.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-tcrm-12-059" position="float"><label>Table 3</label><caption><p>Pathology of resected nodules</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">VATS (n=30)</th><th valign="top" align="left" rowspan="1" colspan="1">Thoracotomy (n=30)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Non-neoplastic</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>11 (36.7)</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>14 (46.7)</bold></td><td valign="top" align="left" rowspan="1" colspan="1">0.546</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pulmonary hamartoma</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.312</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pulmonary granuloma</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.398</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chronic pulmonary inflammation</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.257</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pulmonary fibrosis with fibroblastic plugs</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.818</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Neoplastic primary malignant</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>4 (13.3)</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>3 (10)</bold></td><td valign="top" align="left" rowspan="1" colspan="1">0.398</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NSCLC &#x02013; squamus cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.432</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NSCLC &#x02013; adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.756</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NSCLC &#x02013; large cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.432</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Small-cell lung carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.345</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Neoplastic secondary malignant</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>15 (50)</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>13 (43.3)</bold></td><td valign="top" align="left" rowspan="1" colspan="1">0.414</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Breast carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">5 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.312</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adenocarcinoma of the colon</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.262</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Carcinoma of the larynx</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.257</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Papillary carcinoma of the thyroid gland</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.756</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Malignant melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.388</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bile duct carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.432</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Femoral leiomyosarcoma</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.432</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ovarian carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.432</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Neuroendocrine carcinoma of low differentiation</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.432</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-tcrm-12-059"><p><bold>Notes:</bold> Data are absolute numbers (percentages).</p></fn><fn id="tfn6-tcrm-12-059"><p><bold>Abbreviations:</bold> VATS, video assisted thoracic surgery; NSCLC, non-small-cell lung carcinoma.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-tcrm-12-059" position="float"><label>Table 4</label><caption><p>TNM staging of lung cancer patients and regimen of neoadjuvant therapy used</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Pathology</th><th valign="top" align="left" rowspan="1" colspan="1">TNM stage</th><th valign="top" align="left" rowspan="1" colspan="1">Neoadjuvant therapy</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Squamous cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">T2aN0M0 &#x02013; IB</td><td valign="top" align="left" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">T1bN0M0 &#x02013; IA</td><td valign="top" align="left" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">T2aN0M0 &#x02013; IB</td><td valign="top" align="left" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Large cell carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">T2aN0M0 &#x02013; IB</td><td valign="top" align="left" rowspan="1" colspan="1">None</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Small-cell lung carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">T2bN2M1b &#x02013; IV</td><td valign="top" align="left" rowspan="1" colspan="1">Carboplatin and etoposide Radiotherapy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Small-cell lung carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">T2bN1M0 &#x02013; IIB</td><td valign="top" align="left" rowspan="1" colspan="1">Gemcitabine and carboplatin</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Small-cell lung carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">T2bN2M0 &#x02013; IIIA</td><td valign="top" align="left" rowspan="1" colspan="1">Gemcitabine and carboplatin</td></tr></tbody></table><table-wrap-foot><fn id="tfn7-tcrm-12-059"><p><bold>Abbreviation:</bold> TNM, tumor nodes metastasis.</p></fn></table-wrap-foot></table-wrap></floats-group></article>